Harbor Capital Advisors Inc. Grows Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Harbor Capital Advisors Inc. boosted its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 2.8% during the 4th quarter, Holdings Channel reports. The firm owned 79,648 shares of the company’s stock after buying an additional 2,180 shares during the period. Harbor Capital Advisors Inc.’s holdings in MoonLake Immunotherapeutics were worth $4,313,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics during the third quarter worth $44,000. Quarry LP lifted its stake in MoonLake Immunotherapeutics by 172.7% in the 2nd quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $132,000 after purchasing an additional 1,900 shares in the last quarter. Barclays PLC boosted its holdings in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after purchasing an additional 5,229 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of MoonLake Immunotherapeutics by 26.2% during the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics in the third quarter worth about $706,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Stock Down 3.9 %

NASDAQ MLTX opened at $46.31 on Friday. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $64.98. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -35.90 and a beta of 1.31. The company has a fifty day moving average of $52.18 and a two-hundred day moving average of $48.80.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same period in the previous year, the firm earned ($0.18) EPS. Equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.75 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on MLTX shares. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Friday. Wedbush reiterated an “outperform” rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.43.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.